跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
NUCALA 40 MG SOLUCION INYECTABLE EN JERINGA PRECARGADA - CIMA-AEMPS Drug Approval Details
Approvals
/
CIMA-AEMPS
/
NUCALA 40 MG SOLUCION INYECTABLE EN JERINGA PRECARGADA
Approved
STANDARD
NUCALA 40 MG SOLUCION INYECTABLE EN JERINGA PRECARGADA
Glaxosmithkline Trading Services Limited
🇪🇸 Spanish Agency of Medicines and Medical Devices
Approval Date
Oct 18, 2022
Approval ID
72079ae0c56404f4
Company
Glaxosmithkline Trading Services Limited
Type
Standard
Approval Details
Approval Id
72079ae0c56404f4
Drug Cima Aemps Name
NUCALA 40 MG SOLUCION INYECTABLE EN JERINGA PRECARGADA
Register Number
1151043009
Holder Company Name
Glaxosmithkline Trading Services Limited
Marketing Company Name
Glaxosmithkline S.A.
Holder Company Detail Path
/organization/glaxosmithkline-trading-services-limited
Marketing Company Detail Path
/organization/glaxosmithkline-sa
Authorization Date
2022-10-18
Dosage Form
SOLUCIÓN INYECTABLE EN JERINGA PRECARGADA
Dose
40 MG
Route Of Administration
VÍA SUBCUTÁNEA
Prescription Type
Diagnóstico Hospitalario
Commercialized
Yes
Company Name
Glaxosmithkline Trading Services Limited
Company Detail Path
/organization/glaxosmithkline-trading-services-limited
Company Information
Pharmaceutical Company Name
GLAXOSMITHKLINE TRADING SERVICES LIMITED
Country Name
Spain
City Name
madrid,madrid,country_es
Address
PASEO CASTELLANA 11
Active Ingredients
MEPOLIZUMAB
40 mg
Approved
Quick Info
Agency
CIMA-AEMPS
Country
🇪🇸
Approval Date
Oct 18, 2022
Approval ID
72079ae0c56404f4
Type
Standard
Back to CIMA-AEMPS Approvals